$ News

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

High Growth Tech Stocks In The US For April 2025

April 2025's Promising Penny Stock Highlights

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

Tracking Baker Brothers Portfolio - Q4 2024 Update

Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer

Exploring High Growth Tech Stocks In The US March 2025

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

3 US Penny Stocks With Market Caps Under $200M

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)

US Penny Stocks Spotlight: uCloudlink Group Among 3 Noteworthy Picks

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

2seventy bio: All In On Abecma Multiple Myeloma Treatment

Tracking Baker Brothers Portfolio - Q3 2024 Update

US Penny Stocks To Watch In December 2024

US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results

2seventy bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress